Companies
/
Axtria
Data Analytics
Axtria is a data analytics and technology company providing commercial planning, sales operations, and analytics software specifically for pharmaceutical and life sciences companies.
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Axtria was founded in 2010 by Jassi Chadha and Nitin Shrivastava with a specific focus on the pharmaceutical and broader life sciences industry, an area with distinct and highly regulated commercial operations needs, including managing complex sales territory and incentive compensation structures for pharmaceutical sales representatives, forecasting drug demand, and analyzing prescriber and patient-level data in compliance with healthcare privacy regulations. The company's platform, marketed under names such as Axtria DataMAx and Axtria SalesIQ, helps pharmaceutical and biotech companies plan and manage sales territories, calculate representative incentive compensation, forecast product demand across markets, and analyze commercial performance data, functions that in a heavily regulated, high-stakes industry require both deep domain expertise in pharmaceutical commercial operations and rigorous data governance. The company operates a global delivery model with significant operations in India alongside its U.S. headquarters, reflecting a common structure among enterprise software and analytics services companies serving large corporate clients that value both deep technical capability and cost-efficient delivery at scale. Axtria's customers include many of the world's largest pharmaceutical companies, which rely on the company's software and consulting services to manage increasingly complex, data-intensive commercial operations as drug launches have become more targeted toward specific patient populations and prescriber networks rather than mass-market advertising approaches. The company has increasingly incorporated generative AI and advanced analytics capabilities into its platform to help pharmaceutical commercial teams synthesize market and prescriber data more quickly. Axtria has raised private equity and venture funding, including investment from Warburg Pincus, reaching a valuation in the billions of dollars, and competes with other life sciences commercial analytics vendors as well as broader enterprise data and analytics platforms adapted for pharmaceutical use cases.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
No news available for this company.
